Galectin Therapeutics Inc.
GALT
$5.70
$0.244.40%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.59M | 1.36M | 1.41M | 1.32M | 1.47M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.20M | 4.63M | 7.90M | 12.43M | 9.07M |
| Operating Income | -4.20M | -4.63M | -7.90M | -12.43M | -9.07M |
| Income Before Tax | -8.18M | -7.52M | -9.63M | -11.97M | -11.22M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.18M | -7.52M | -9.63M | -11.97M | -11.22M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.18M | -7.52M | -9.63M | -11.97M | -11.22M |
| EBIT | -4.20M | -4.63M | -7.90M | -12.43M | -9.07M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.13 | -0.12 | -0.15 | -0.19 | -0.18 |
| Normalized Basic EPS | -0.08 | -0.07 | -0.10 | -0.12 | -0.11 |
| EPS Diluted | -0.13 | -0.12 | -0.15 | -0.19 | -0.18 |
| Normalized Diluted EPS | -0.08 | -0.07 | -0.10 | -0.12 | -0.11 |
| Average Basic Shares Outstanding | 64.21M | 63.45M | 63.20M | 62.75M | 62.28M |
| Average Diluted Shares Outstanding | 64.21M | 63.45M | 63.20M | 62.75M | 62.28M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |